FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104099737> ?p ?o ?g. }

• W2104099737 endingPage "350" @default.
• W2104099737 startingPage "343" @default.
• W2104099737 abstract "PURPOSE The purpose of this study was to evaluate the efficacy and tolerance of recombinant human interferon gamma (rIFN-gamma) as second-line treatment in patients with persistent disease at second-look laparotomy. PATIENTS AND METHODS One hundred eight patients with residual disease at second-look laparotomy were treated with rIFN-gamma (20 x 10(6) IU/m2) administered intraperitoneally (IP) twice a week for 3 to 4 months. In the absence of clinically assessable disease, response to rIFN-gamma was assessed with a third-look laparotomy. RESULTS Of 98 assessable patients, 31 (32%) achieved a surgically documented response, including 23 patients (23%) with a complete response (CR). The age and size of residual tumor were significant prognostic factors for the response to rIFN-gamma. A 41% CR rate was observed in 41 patients younger than 60 years and with residual tumor less than 2 cm. The probability of response was independent of previous response to first-line chemotherapy. The median duration of response was 20 months and the 3-year survival rate in responders was 62%. Response to rIFN-gamma was the most significant prognostic factor for survival of patients with residual disease. Adverse events included fever, flu-like syndrome, neutropenia, and liver enzyme disturbances. No significant peritoneal fibrosis was noted. CONCLUSION These results support the potential interest of IP rIFN-gamma as adjuvant treatment in ovarian cancer. Controlled prospective trials are required to determine its place in the therapeutic strategy of this malignancy." @default.
• W2104099737 created "2016-06-24" @default.
• W2104099737 creator A5012804079 @default.
• W2104099737 creator A5013155002 @default.
• W2104099737 creator A5017495356 @default.
• W2104099737 creator A5018514406 @default.
• W2104099737 creator A5030347520 @default.
• W2104099737 creator A5030495694 @default.
• W2104099737 creator A5043141361 @default.
• W2104099737 creator A5052299853 @default.
• W2104099737 creator A5054483323 @default.
• W2104099737 creator A5066888430 @default.
• W2104099737 creator A5071498546 @default.
• W2104099737 creator A5071867163 @default.
• W2104099737 creator A5073063132 @default.
• W2104099737 creator A5073836275 @default.
• W2104099737 creator A5080012180 @default.
• W2104099737 creator A5089385974 @default.
• W2104099737 date "1996-02-01" @default.
• W2104099737 modified "2023-09-26" @default.
• W2104099737 title "Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy." @default.
• W2104099737 cites W1499684074 @default.
• W2104099737 cites W1562850075 @default.
• W2104099737 cites W1599084706 @default.
• W2104099737 cites W1673523545 @default.
• W2104099737 cites W1764997972 @default.
• W2104099737 cites W1965463442 @default.
• W2104099737 cites W1972862264 @default.
• W2104099737 cites W1974545871 @default.
• W2104099737 cites W1976548176 @default.
• W2104099737 cites W1987689578 @default.
• W2104099737 cites W1991011743 @default.
• W2104099737 cites W2009228522 @default.
• W2104099737 cites W2015789213 @default.
• W2104099737 cites W2021914855 @default.
• W2104099737 cites W2021977722 @default.
• W2104099737 cites W2029572946 @default.
• W2104099737 cites W2034279045 @default.
• W2104099737 cites W2036545336 @default.
• W2104099737 cites W2038461466 @default.
• W2104099737 cites W2042103706 @default.
• W2104099737 cites W2042149437 @default.
• W2104099737 cites W2042967546 @default.
• W2104099737 cites W2043289036 @default.
• W2104099737 cites W2061883989 @default.
• W2104099737 cites W2066656768 @default.
• W2104099737 cites W2076261472 @default.
• W2104099737 cites W2077443254 @default.
• W2104099737 cites W2081517449 @default.
• W2104099737 cites W2084500050 @default.
• W2104099737 cites W2086504551 @default.
• W2104099737 cites W2087143702 @default.
• W2104099737 cites W2103862203 @default.
• W2104099737 cites W2107272391 @default.
• W2104099737 cites W2111636750 @default.
• W2104099737 cites W2119782637 @default.
• W2104099737 cites W2127262158 @default.
• W2104099737 cites W2136293508 @default.
• W2104099737 cites W2136548258 @default.
• W2104099737 cites W2137332723 @default.
• W2104099737 cites W2161530231 @default.
• W2104099737 cites W2164675068 @default.
• W2104099737 cites W2173056030 @default.
• W2104099737 cites W2173197466 @default.
• W2104099737 cites W2233693505 @default.
• W2104099737 cites W2234488796 @default.
• W2104099737 cites W2241933379 @default.
• W2104099737 cites W2319083682 @default.
• W2104099737 cites W2337014572 @default.
• W2104099737 cites W2404340552 @default.
• W2104099737 cites W2414752575 @default.
• W2104099737 cites W2415206593 @default.
• W2104099737 cites W2415997304 @default.
• W2104099737 cites W2419272721 @default.
• W2104099737 cites W585577023 @default.
• W2104099737 doi "https://doi.org/10.1200/jco.1996.14.2.343" @default.
• W2104099737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8636742" @default.
• W2104099737 hasPublicationYear "1996" @default.
• W2104099737 type Work @default.
• W2104099737 sameAs 2104099737 @default.
• W2104099737 citedByCount "149" @default.
• W2104099737 countsByYear W21040997372012 @default.
• W2104099737 countsByYear W21040997372013 @default.
• W2104099737 countsByYear W21040997372014 @default.
• W2104099737 countsByYear W21040997372015 @default.
• W2104099737 countsByYear W21040997372016 @default.
• W2104099737 countsByYear W21040997372017 @default.
• W2104099737 countsByYear W21040997372018 @default.
• W2104099737 countsByYear W21040997372019 @default.
• W2104099737 countsByYear W21040997372020 @default.
• W2104099737 countsByYear W21040997372021 @default.
• W2104099737 countsByYear W21040997372022 @default.
• W2104099737 countsByYear W21040997372023 @default.
• W2104099737 crossrefType "journal-article" @default.
• W2104099737 hasAuthorship W2104099737A5012804079 @default.
• W2104099737 hasAuthorship W2104099737A5013155002 @default.
• W2104099737 hasAuthorship W2104099737A5017495356 @default.
• W2104099737 hasAuthorship W2104099737A5018514406 @default.

• next